financetom
Business
financetom
/
Business
/
EU probes on Chinese subsidies and imports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
EU probes on Chinese subsidies and imports
May 5, 2024 7:53 AM

(Reuters) -The European Union launched an investigation into China's procurement of medical devices on Wednesday in a latest effort to protect home-grown manufacturers.

It has also launched several probes into whether Chinese clean tech producers are dumping subsidised goods on its market and whether Chinese-owned companies unfairly benefit from subsidies while operating inside the EU.

The European Commission, which is carrying out the investigations, says its aim is to prevent unfair competition and market distortion.

Here's what you need to know about the investigations:

MEDICAL DEVICES

The European Commission launched a probe into Chinese public procurement of medical devices, the EU's official journal said on April 24.

The investigation is the first under the EU International Procurement Instrument, which aims to prevent countries from unfairly favouring domestic suppliers.

If the Commission finds that European suppliers don't have fair access to the Chinese market, it could place restrictions on Chinese medical device companies bidding in EU public tenders.

The investigation is to be concluded within nine months, although the Commission can extend this period by a further five months.

WIND TURBINES

The EU is investigating subsidies received by Chinese suppliers of wind turbines destined for Europe, the bloc's anti-trust commissioner Margrethe Vestager said on April 9.

It will look into wind park development in Spain, Greece, France, Romania and Bulgaria, Vestager said without naming specific companies.

China said the probe was "discriminatory" against Chinese enterprises and endorsed protectionism.

SOLAR PANELS

The Commission opened two investigations under the EU Foreign Subsidies Regulation (FSR) into whether two Chinese bidders benefited excessively from subsidies in their offers in a public tender for a solar power park in Romania, it said on April 3.

The investigations concern a consortium composed of Romania's ENEVO and a unit of China's LONGi, and subsidiaries of Chinese state-owned Shanghai Electric Group.

The Commission has until Aug. 14 to take a decision on whether to block the contract, accept commitments from the companies to eliminate the distortion of competition, or not to object.

The Commission's first investigation launched under the FSR, concerning a Chinese train maker's participation in a Bulgarian tender for electric trains, ended after CRRC Qingdao Sifang Locomotive withdrew its tender.

ELECTRIC VEHICLES

The Commission said on Sept. 13 it would launch an anti-subsidy investigation into Chinese electric vehicles to determine whether to impose punitive tariffs on them.

It wants to find out if Chinese exports of EVs to the EU market are benefitting from excessive subsidies.

China's commerce minister Wang Wentao said in April that U.S. and European assertions of excess Chinese EV capacity were baseless, while a Chinese industry body said the probe was stacked against Chinese manufacturers.

The investigation, officially launched on Oct. 4, will last up to 13 months. The Commission can impose provisional anti-subsidy duties nine months after the start of the probe.

(Compiled by Chiara Holzhaeuser, Agnieszka Olenska and Philippe Leroy Beaulieu; Edited by Milla Nissi and Mark Potter)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Novo Nordisk Partners with GoodRx to Slash Ozempic, Wegovy Prices to $499 Per Month
Novo Nordisk Partners with GoodRx to Slash Ozempic, Wegovy Prices to $499 Per Month
Aug 18, 2025
09:17 AM EDT, 08/18/2025 (MT Newswires) -- GoodRx ( GDRX ) said Monday it is partnering with Novo Nordisk ( NVO ) to offer Ozempic and Wegovy pens at the significantly lower price of $499 per month. ...
Invesque Completes Disposition of Remaining Skilled Nursing Facilities and Fully Repays KeyBank Credit Facility
Invesque Completes Disposition of Remaining Skilled Nursing Facilities and Fully Repays KeyBank Credit Facility
Aug 18, 2025
09:15 AM EDT, 08/18/2025 (MT Newswires) -- Invesque ( MHIVF ) on Monday said it that it sold its two remaining skilled nursing facilities in Illinois which were previously leased via a long-term, triple-net lease that included a tenant purchase option. The company said proceeds from the deal allowed it to fully repay the KeyBank credit facility. Invesque ( MHIVF...
Novo Nordisk to offer Ozempic at $499 per month to cash-paying US customers
Novo Nordisk to offer Ozempic at $499 per month to cash-paying US customers
Aug 18, 2025
Aug 18 (Reuters) - Novo Nordisk said on Monday that it was launching a new offer for self-paying type 2 diabetes patients in the U.S. to access Ozempic for $499 per month. The company said this was part of its ongoing efforts to explore new collaborations and approaches towards improving access to authentic semaglutide medicines. It said the offer would...
Update: Market Chatter: Jefferies Financial Hires JPMorgan's Melly as APAC FIG Deals Head
Update: Market Chatter: Jefferies Financial Hires JPMorgan's Melly as APAC FIG Deals Head
Aug 18, 2025
09:17 AM EDT, 08/18/2025 (MT Newswires) -- (Updates with Jefferies Financial ( JEF ) response in the last paragraph.) Jefferies Financial Group ( JEF ) is bringing on Michael Melly from JPMorgan ( JPM ) to head its financial institutions group investment banking franchise for Asia-Pacific, Bloomberg News reported Sunday, citing people familiar with the matter. Melly is expected to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved